Business
-
Apollo Global Management has agreed to acquire Covis Pharma, which markets several ciclesonide aerosol products: the Alvesco MDI and Omnaris and Zetonna nasal sprays. Terms of the deal were not disclosed. Covis is currently owned… Read more . . .
-
Boehringer Ingelheim’s reusable Respimat soft mist inhaler has won the 2020 Pharmapack Eco-Design Award, the company said. As many as six medication cartridges can be used with this version of the Respimat before the device must… Read more . . .
-
According to Novartis’s 2019 annual report, Novartis subsidiary Sandoz has discontinued development of a generic version of the Advair Diskus fluticasone propionate/salmeterol DPI for the treatment of asthma and COPD for the US market as… Read more . . .
-
Days after announcing that the FDA has accepted its NDA resubmission for Gimoti metoclopramide nasal spray for the treatment of diabetic gastroparesis, Evoke Pharma said that the company has cancelled a previously announced commercialization deal… Read more . . .
-
AstraZeneca has announced a commitment to launching a “next-generation” MDI with minimal global warming potential (GWP) propellants by 2025 as part of its $1 billion “Ambition Zero Carbon” program. The new program, which was announced… Read more . . .
-
Virpax Pharmaceuticals announced that it has acquired exclusive global rights from Nanomerics Ltd. for the use of molecular envelope technology (MET) for delivery of an intranasal formulation of enkephalin for the treatment of PTSD. The company… Read more . . .
-
Altavant Sciences has announced its acquisition of Onspira Therapeutics, which apparently had a single candidate in its pipeline: OSP-101, an inhaled interleukin-1 receptor antagonist. In August 2018, the FDA granted Orphan Drug designation to OSP-101… Read more . . .
-
AI Therapeutics (formerly LAM Therapeutics) said that it is seeking a partner to advance its LAM-001 inhaled rapamycin into Phase 3 trials for the treatment of lymphangioleiomyomatosis (LAM disease) and into Phase 2 for the… Read more . . .
-
According to MannKind Corporation, Brazil’s Drug Market Regulation Chamber (CMED) has approved the proposed pricing for Afrezza inhaled insulin, and the Afrezza DPI is set to launch in Brazil within the next week. The Brazilian Health… Read more . . .
-
Canadian CRO Impopharma, which specializes in OINDP analysis and development, has been acquired by Rubicon Research, Rubicon said. Impopharma’s Concord, ON facility will become Rubicon’s Nasal and Pulmonary Center of Excellence. Impopharma’s services included testing… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
May 10-May 14: RDD 2026, Phoenix, AZ, USA
May 15-May 16: ATS Respiratory Innovation Summit 2026, Orlando, FL, USA
May 17-May 20: ATS International Conference 2026, Orlando, FL, USA
June 10: SMI.London 2026, London, UK
July 13-July 16: 2026 ISAM Congress, Taipei, Taiwan